TK216

TK216 is a small molecule investigational drug designed as an inhibitor of E26 transformation-specific (ETS) family transcription factors, with a primary focus on directly binding and inhibiting the EWS-FLI1 fusion protein. This mechanism disrupts protein-protein interactions essential for the oncogenic activity of EWS-FLI1, thereby inhibiting its transcriptional function. TK216 has demonstrated anticancer activity, particularly in preclinical and clinical studies targeting Ewing sarcoma and other cancers characterized by aberrant ETS activity. The drug is being developed for use in relapsed or refractory Ewing sarcoma, often in combination with vincristine[1][2][4][5][6]. Preclinical data also suggest potential efficacy against pediatric acute myeloid leukemia (AML) and B-cell acute lymphoblastic leukemia (B-ALL)[6].